The SR-B1 Receptor as a Potential Target for Treating Glioblastoma

Table 3

IC₅₀ of everolimus (EVR) formulations against glioblastoma cells (LN 229 and U87) and astrocytes.

Cell line	Free-EVR (µM)	rHDL-EVR (µM)
LN229	>50	0.27±0.05
U87	2.91±0.3	0.92±0.17
Astrocytes	4.27±0.82	15.1±1.24

Note: a range of concentration of 10 nM to 50 µM of each formulation was used for the cytotoxicity studies.